Market Cap 32.86M
Revenue (ttm) 0.00
Net Income (ttm) -21.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 166,600
Avg Vol 66,122
Day's Range N/A - N/A
Shares Out 1.34M
Stochastic %K 75%
Beta -0.26
Analysts Strong Sell
Price Target $55.50

Company Profile

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103,...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 243 8000
Address:
1405 Research Boulevard, Suite 125, Rockville, United States
Latest News on FTH
Faeth Therapeutics initiated with an Outperform at Baird

2026-06-25T20:21:04.000Z - 12 days ago

Faeth Therapeutics initiated with an Outperform at Baird


Faeth Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-22T10:09:32.000Z - 15 days ago

Faeth Therapeutics initiated with a Buy at H.C. Wainwright


Faeth Therapeutics files automatic mixed securities shelf

2026-06-18T20:05:40.000Z - 19 days ago

Faeth Therapeutics files automatic mixed securities shelf


Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

Jun 13, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split


Sensei Biotherapeutics to Present at Upcoming Conferences

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences